Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

Inclusion Criteria

Concurrent Medication:

Allowed:

* Ibuprofen.
* Standard antiemetic agents.
* Ganciclovir therapy for sight- or life-threatening Cytomegalovirus infection.
* Zidovudine and methotrexate may be resumed during ganciclovir maintenance phase.

Exclusion Criteria

Co-existing Condition:

The following patients will be excluded from the study:

* Patients with recurrent infection that may interfere with the planned protocol.
* Patients with a second active tumor other than nonmelanomatous skin cancer or Kaposi's sarcoma.
* Patients with stage IE primary central nervous system lymphoma.

Concurrent Medication:

Excluded:

* Corticosteroids.
* Aspirin.
* Acetaminophen.
* Nonsteroidal anti-inflammatory drugs, except ibuprofen.
* Chemotherapy for infection associated with neutropenia.
* Zidovudine (AZT) for infection associated with neutropenia.
* Investigational therapies, except ganciclovir therapy for sight- or life-threatening cytomegalovirus infection.
* AZT and methotrexate will be suspended during induction therapy with ganciclovir.

The following patients will be excluded from the study:

* Patients with recurrent infection that may interfere with the planned protocol.
* Patients with a second active tumor other than nonmelanomatous skin cancer or Kaposi's sarcoma.
* Patients with stage IE primary central nervous system lymphoma.

Prior Medication:

Excluded:

* Zidovudine (AZT).
* Excluded within 2 weeks of study entry:
* Immunomodulating agents.
* Antiretroviral therapy prior to diagnosis of lymphoma.

Patients must demonstrate the following clinical and laboratory findings:

* Any stage of the disease, including stage I.
* Newly diagnosed, previously untreated high-grade lymphoma.
* Presence of measurable tumor parameter(s).
* Adequate hepatic, renal, and bone marrow function.